CliffBio
biologic

Gonal-f RFF RediJect

follitropin alfa

Loss of exclusivityMay 2016projected — 12-year biologic exclusivity estimate
CompanyEMD Serono →See this company's full patent-cliff portfolio

Drug detail

Brand nameGonal-f RFF RediJect
Active ingredientfollitropin alfa
Strength900IU/1.5ML
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalMay 2004
Marketing statusRx

More from EMD Serono

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Gonal-f RFF RediJect patent cliff — loss of exclusivity May 2016 | CliffBio